128270-60-0
Chemical Structure
Bivalirudin
- CAS No.: 128270-60-0
- Formula:C98H138N24O33
- Molecular Weight:2180.29
InChIKey: OIRCOABEOLEUMC-GEJPAHFPSA-N
SMILES: O=C([C@H]1N(CCC1)C([C@H](CCCNC(N)=N)NC([C@H]2N(CCC2)C([C@H](N)CC3=CC=CC=C3)=O)=O)=O)NCC(NCC(NCC(NCC(N[C@@H](CC(N)=O)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(N5[C@@H](CCC5)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@H](C(O)=O)CC(C)C)=O)CC6=CC=C(C=C6)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bivalirudin | 99.97% | Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ye H, et al. Bivalirudin Attenuates Thrombin-Induced Endothelial Hyperpermeability via S1P/S1PR2 Category: Original Articles. Front Pharmacol. 2021 Aug 3;12:721200. [Content Brief]
- [2]. Zhuang S, et al. Bivalirudin exerts antiviral activity against respiratory syncytial virus-induced lung infections in neonatal mice. Acta Pharm. 2022 Apr 13;72(3):415-425. [Content Brief]
- [3]. André P, et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.Circulation. 2003 Nov 25;108(21):2697-703. [Content Brief]
- [4]. Warkentin TE, et al. Bivalirudin: a review. Expert Opin Pharmacother. 2005 Jul;6(8):1349-71. [Content Brief]
